Detection of Circulating Tumor Cells in Patients with Breast, Prostate, Pancreatic, Colon and Melanoma Cancer: A Blinded Comparative Study Using Healthy Donors

Papasotiriou, Ioannis; Chatziioannou, Marina; Pessiou, Konstantina; Retsas, Ippokratis; Dafouli, Georgia; Kyriazopoulou, Antigoni; Toloudi, Maria; Kaliara, Irene; Vlachou, Ioanna; Kourtidou, Eleni; Kipourou, Vasiliki; Georgiou, Εvanthia; Ntanovasilis, Dimitrios Athanasios; Theodosiou, Christos; Pantopikou, Aikaterini; Apostolou, Panagiotis

doi:10.4236/jct.2015.67059

Cited by 8 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the patients were assessed using a circulating tumour cell test before and after treatment (11), since this is cheaper than carrying out repeated scans. A number of patients however, as a matter of a normal treatment course, had relevant scans.…”

Section: Case Presentationsmentioning

confidence: 99%

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol

2018

View full text Add to dashboard Cite

Background/Aim: Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of pharmaceutical-grade synthetic cannabidiol on a range of cancer patients. Patients and Methods: We analysed the data routinely collected, as part of our treatment program, in 119 cancer patients over a fouryear period. Results: Clinical responses were seen in 92% of the 119 cases with solid tumours including a reduction in circulating tumour cells in many cases and in other cases, a reduction in tumour size, as shown by repeat scans. No sideeffects of any kind were observed when using pharmaceutical grade synthetic cannabidiol. Conclusion: Pharmaceuticalgrade synthetic cannabidiol is a candidate for treating breast cancer and glioma patients. 5831

show abstract

Section: Case Presentationsmentioning

confidence: 99%

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol

2018

View full text Add to dashboard Cite

show abstract

“…A number of methods have been established for detection and isolation of CTCs, and each method has advantages and disadvantages [ 1 ]. The CTCs are generally isolated from whole blood using enrichment protocols or flow cytometry [ 2 – 5 ]. A major problem is the stability of this cell population during transportation; collected blood should be handled with care, as any mechanical trauma can be detrimental to the viability of the cells [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96 h after sample collection

Apostolou¹,

Ntanovasilis²,

Papasotiriou³

2017

J of Biol Res-Thessaloniki

Self Cite

View full text Add to dashboard Cite

BackgroundMinimizing the effects of transportation on the properties of biological material is a major challenge for the scientific community. The viability of cells is important in cases where their study is urgent for evaluation of treatment response or for the study of cancer progression. Circulating tumor cells (CTCs) constitute a cell subpopulation with great importance for oncologists, because of their prognostic value. Detection and isolation of CTCs from blood samples is a routine activity in many laboratories, but concerns exist with regard to the maintenance of the cells during transportation. In this study, experiments were conducted to determine the stability of gene and protein expression in CTCs over a period of 96 h.ResultsBlood samples collected from healthy individuals and patients with cancer were each divided into five aliquots, which were stored at 2–8 °C and analyzed after 0, 24, 48, 72 and 96 h of storage. CTCs from patients and CD45-negative cells from healthy individuals were isolated each day using enrichment protocols, and qPCR was performed to determine expression levels of genes encoding specific biological markers. In addition, cells from breast and colon cancer cell lines were spiked into blood samples from healthy individuals, and these samples were stored and analyzed over a period of 96 h by PCR and by flow cytometry. The markers that were studied included housekeeping genes and genes associated with the response to chemotherapy, as well as genes encoding transcription factors. The results demonstrated that the expression profiles of specific genes and proteins in CTCs were not significantly affected by 72 h of storage. After 96 h of storage, expression of some genes was altered.ConclusionThe transportation of blood at low temperature (2–8 °C) in the presence of the anticoagulant EDTA can protect CTCs from alteration of gene and protein expression for at least 72 h. Furthermore, under these conditions, CTCs can be detected and isolated 96 h after blood collection.

show abstract

“…This side effect did not persist. All cases showed a response either in circulating tumor cells [19,20], in those who had this test done or in reducing PSA levels. All of those who stopped taking PGSC showed a subsequent increase in circulating tumor cells or in PSA.…”

Section: Resultsmentioning

confidence: 98%

“…Patients on continuous dosing did not do as well as those on an on/off repeating regimen. We assessed the majority of patients using circulating tumor cells tests [19,20]; some decided not to have this.…”

Section: Methodsmentioning

confidence: 99%

Report of Objective Responses of Prostate Cancer Patients to Pharmaceutical Grade Synthetic Cannabidiol

Kenyon¹,

Davies²,

Stott³

2020

CRIO

View full text Add to dashboard Cite

show abstract

Detection of Circulating Tumor Cells in Patients with Breast, Prostate, Pancreatic, Colon and Melanoma Cancer: A Blinded Comparative Study Using Healthy Donors

Cited by 8 publications

References 36 publications

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol

Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96 h after sample collection

Report of Objective Responses of Prostate Cancer Patients to Pharmaceutical Grade Synthetic Cannabidiol

Contact Info

Product

Resources

About